Reducing immune rejection related therapies using "stealth" technologies

This Clarity Insight was a logical extension to the biobanking and off-the-shelf therapy insights. Concerns of Graft vs Host Disease remain a concern to this day. Nevertheless, many technologies and gene modifications are possible to today thanks to advancement in the field. This insight shares some perspective on the matter.

Previous
Previous

Proud to announce the publication of the CCRM Australia 2025 Impact Report.

Next
Next

Biobanks are paving the way for personalised medicine